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Mucosal surfaces are the first site of infection for most infectious diseases and oral
vaccination can provide protection as the first line of defense. Unlike systemic
administration, oral immunization can stimulate cellular and humoral immune responses
at both systemic and mucosal levels to induce broad-spectrum and long-lasting immunity.
Therefore, to design a successful vaccine, it is essential to stimulate the mucosal as well as
systemic immune responses. Successful oral vaccines need to overcome the harsh
gastrointestinal environment such as the extremely low pH, proteolytic enzymes, bile
salts as well as low permeability and the low immunogenicity of vaccines. In recent years,
several delivery systems and adjuvants have been developed for improving oral vaccine
delivery and immunogenicity. Formulation of vaccines with nanoparticles and
microparticles have been shown to improve antigen stability, availability and
adjuvanticity as well as immunostimulatory capacity, target delivery and specific
release. This review discusses how nanoparticles (NPs) and microparticles (MPs) as
oral carriers with adjuvant characteristics can be beneficial in oral vaccine development.
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INTRODUCTION
Mucosal immunization has numerous advantages over parenteral (needle-based) administrations
such as socio-economic benefits, relatively improved safety by a lower risk of needle injury infection/
inflammation, self-delivery, capacity for mass immunizations, no special training required, patient
compliances and ability to elicit mucosal immune responses (Corthésy and Bioley, 2018). Mucosal
membranes are exposed to antigenic substances which can induce specific antibody as well as cell-
mediated immune responses through the secretory IgA (sIgA) that could prevent the attachment of
bacteria and viruses to the mucosa and plays a major role in mucosal protection. The IgA following
oral vaccination could migrate to distant mucosal sites, like respiratory and urinogenital mucosa, by
forming a defense network against bacterial and viral pathogens (Pietrzak et al., 2020).
Intranasal and oral routes are both considered as the main options for mucosal immunization. As
intranasal immunization could have some harmful effects on people with asthma and other chronic
pulmonary or cardiovascular disorders, the oral route appears to be the safest, more applicable and
most preferred mode of vaccination for the development of new generation vaccines.
The gastrointestinal (GI) tract of humans has over 260–300 m2 of the mucosal surface containing
immune inductive tissues such as Peyer’s patches (in the small intestine), lymphoid follicles (large
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intestine) and intraepithelial lymphocytes which are important
for antigen presentation and appropriate functioning of the
immune system Zhang et al. (2018).
Currently, a limited number of oral vaccines that have been
licensed for human use are using live attenuated (Polio; OPV,
Typhoid; Vivotif, Cholera; Orochol, Rotavirus; Rotarix and
RotaTeq) or whole inactivated pathogens (Cholera; Dukoral)
(Mwanza-Lisulo and Kelly, 2015). The commercially available
oral vaccines have shown high efficacy in industrialized countries
but much lower efficacy in low or middle-income countries
(Lestari et al., 2020). Although the impaired efficacy is not
very well understood, some possibilities for the lower efficacy
included nutritional factors such as vitamin A, interaction with
the high titers of antibody in maternal breast milk, environmental
enteropathy (Qadri et al., 2013) and Helicobacter pylori infection
(Muhsen et al., 2014).
On the other hand, oral vaccine (peptide, DNA, or RNA-
based) delivery has always been a significant challenge for
pharmaceutical technology and vaccine development due to its
very poor bioavailability through the GI tract. The possible
explanation for the low oral absorption of the vaccines might
include enzymatic degradation, poor membrane penetration,
hepatic metabolism and the unique physicochemical
characteristics of the GI mucosa (Xu et al., 2018).
As the GI tract is continuously exposed to a broad range of
pathogens, successful oral vaccines need to induce appropriate
strong signals to be recognized by the immune system, otherwise,
the host immune system would consider the vaccines as non-
immunogenic and resulting in immune tolerance instead of
conferring broad protection. Therefore, it is important to
design an effective vaccine carrier including safe effective
adjuvants to sufficiently stimulate the mucosal immune system
(Vela Ramirez et al., 2017). An ideal oral vaccine carrier is
expected to protect the antigens from degradation through the
GI tract, deliver sufficient antigens to the inductive mucosal
surface, enhance antigen uptake, activate immune cells,
produce effective long-lasting mucosal and systemic immune
responses. During recent years, various strategies have been
developed for effective oral vaccine delivery, such as enzyme
inhibitors, encapsulation into particulate delivery systems,
chemical modifications, preparation of macromolecular
conjugation and targeted delivery to the colon. Nevertheless,
based on currently available data none of these approaches
could be considered as a breakthrough.
Most of the soluble antigens are unable to be efficiently
endocytosed by the antigen-presenting cells (APCs) and
cannot induce any protective immunity. Conjugation or
encapsulation of soluble antigens with nanocarriers could
improve their immunogenicity and facilitate recognition and
uptake of antigens by APCs. Therefore, the immunogenicity of
soluble antigens could be improved by conjugation or
encapsulation with nanocarriers that could facilitate the
recognition and uptake by APCs (Pati et al., 2018). Several
oral vaccine formulations are currently being explored based
on nanoparticles (NPs) and microparticles (MPs). NPs and
MPs can be administered via subcutaneous, intramuscular or
through mucosal sites (oral and intranasal routes) as well as
penetrating capillaries. Incorporation of antigens in NPs andMPs
could be achieved by physical encapsulation or by covalent
conjugation (Chattopadhyay et al., 2017). Encapsulation could
protect the structure of antigens against proteolytic degradation,
improve immunostimulatory effects and antigen delivery to
APCs. Due to poor immunogenicity of recombinant and
synthetic antigens in different vaccine platforms, an adjuvant
in vaccine formulation could increase immunogenicity, reduce
the amount of antigens, improve the immune responses and
protection (Wang and Xu, 2020). This review focuses on the
potential applications of various types of NP and MP systems as
novel delivery and enhancement of adjuvanticity for oral vaccine
development against infectious diseases.
THE MICROFOLD-CELLS
The surface of the GI tract contains a chemical and physical
barrier formed by an impermeable layer of epithelial cells. The M
cells are mainly located within the epithelium of Peyer’s patches
in the ileum and have some noticeable features for the uptake of
particles. However, the lower percentage of M cells in the GI tract
(1% of the total surface of the intestine) causes significant
problems in humans towards oral vaccine development. The
efficacy of oral vaccination is mostly impaired due to the low
populations of M cells in the intestines. To increase the efficiency
of the delivery of oral vaccines, it is necessary to target the vaccine
complex to M cells. Various absorption parameters that play an
important role in the uptake of NPs/MPs via M cells include
particle size, charge, hydrophobicity/hydrophilicity balance and
existence of a targeting molecule at the surface of the particles.
Generally, M cells could uptake particles ranging from below 1 µ
to above 5 µ in size. Particles smaller than 1 µ are passed into the
basal medium, while particles above 5 µ are delivered to Peyer’s
patches. The optimum size of NPs for transcytosis by M cells is
proposed to be smaller than 200 nm. The formulation of
negatively charged and hydrophobic particles is favorable
because of the optimal absorption by M cells (Des Rieux et al.,
2006).
The intestinal immune system is regulated by gut-associated
lymphoid tissues (GALT) which contain inductive and effector
sites. Inductive tissues include the Peyer’s patches, lymphoid
follicles (within lymph nodes), and APCs. Meanwhile, effector
sites comprise the lamina propria and the surface epithelium.
After oral administration with particulate vaccines, antigens
could migrate through the GI tract.
After entering the small intestine, specialized M cells in the
Peyer’s patches sample and transport the antigens across to APCs.
The antigens are processed into small fragments by DCs that
present antigenic fragments on their surface.
These antigen-loaded DCs provide costimulatory signals to
activate naive CD4 T cells. The primed helper T cells further
interact with antigen-specific B-cells that undergo class-switching
to become immunoglobulin-secreting cells.
Upon maturation, IgA B cells leave the Peyer’s patches
through afferent lymphatics to the regional mesenteric lymph
node before reaching the systemic blood circulation (Figure 1)
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(Brayden et al., 2005; Marasini et al., 2014; Vela Ramirez et al.,
2017). Finally, the circulating antigen-specific IgA secreting
B cells migrate to distant effector sites in the lamina propria
undergo differentiation and maturation to generate high-affinity
IgA producing plasma cells which produce the dimeric or
polymeric form of IgA. The dimeric or polymeric IgA binds to
polymeric Ig receptors expressed on the basolateral surface of
epithelial cells to form SIgA which further translocates toward the
luminal surface of the intestine (Marasini et al., 2014).
ADJUVANTS
Adjuvants originated from the Latin word “adjuvare”, which
means “aid or to help” and was first explained by Ramon in
1924 as “substances used in combination with a specific antigen
to enhance the immunological responses” (Awate et al., 2013).
Generally, adjuvants are non-specific immunopotentiators
which together with the antigen(s), could boost the body’s
immune responses as well as changing the type of the immune
response (Jin et al., 2019).
Aluminum salts, developed in the United States in the 1920s
and for more than 7 years, was the only adjuvant available in the
United States until MF59 (incorporated in influenza vaccine) was
approved in the 1990s (Del Giudice et al., 2018).
Alum is still an important component of most licensed human
vaccines like human papillomavirus (HPV), Hepatitis A virus
(HAV), diphtheria, Hepatitis B virus (HBV), Haemophilus,
Influenzae Type b (Hib), tetanus, and meningococcal vaccines
(Lee and Nguyen, 2015).
Alum as a potential adjuvant have been tested in the
formulations of a few under exploratory and pre-clinical
coronavirus vaccine investigations. Liang et al. (2020)
demonstrated formulation of alum with S protein or receptor-
binding domain (RBD) which significantly improved the titers of
IgG1 in serum, increased high affinity of neutralizing antibodies
as well as generated long-lasting memory B cells in mice (Liang
et al., 2020).
FIGURE 1 | Schematic diagram of mucosal immune induction to generate T-cell-dependent IgA production. The particulate antigens in intestinal lumen are moved
across the intestinal epithelium barrier by sampling M cells, transcytosed and presented to DCs. The antigen-loaded DCs (activated DCs) could travel and prime naïve
CD4 T cells in Peyer’s patches. Primed CD4 T cells then activate B cells, which undergo isotype switching, thus generating antigen-specific IgA+ B cells. These IgA+
B cells leave the Peyer’s patches through the afferent lymph system to mesenteric lymph node, enter the blood circulation and reach effector sites in the lamina
propria, mature, and become IgA producing-plasma B cells. The dimeric or polymeric IgA binds to Ig receptors expressed on the basolateral surface of epithelial cells to
form SIgA. The figure is made with biorender (https://biorender.com/).
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Furthermore, virus-like particle (VLP) and inactivated
vaccines containing E, M, and N proteins were formulated
with Alum and showed enhanced IgG1 and neutralizing
antibody titers and prolonged durability. Studies also
demonstrated that alum adjuvant plays an essential role in the
dose-sparing of CoV vaccines (Liang et al., 2020). Moreover,
FIGURE 2 | Timeline of licensed vaccine adjuvants. Aluminium salt was the first and most used adjuvant with other limited adjuvants such as MF59, virosome,
AS01, AS03, AS04 and CpG ODN which are used in FDA-approved vaccines for humans.
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recently Gao et al. (2020) showed that a purified inactivated
SARS-CoV-2 vaccine in combination with aluminum hydroxide
as adjuvant could provide complete protection in rhesus
macaques with potent humoral responses and with no lung
immunopathology (Gao et al., 2020).
Aluminum-based adjuvant might be sufficient for eliciting
humoral immune responses with acceptable safety and efficiency,
but it is a poor immunostimulator of cellular immune responses
and has limited application as an adjuvant for vaccination against
intracellular pathogens. Aluminum is not effective at triggering
the molecular events that support IgA class switching,
recombination or homing of activated T and B cells in
mucosal tissues (Reed et al., 2009). Therefore, new generation
of adjuvants for improvement of the immunogenicity of weak
antigens (Ags), with limited or no toxicity and side effects,
effective with low-dose Ags, suitable with many different Ags,
effective enough to reduce the number of immunisations,
simultaneous stimulations of humoral, cellular and mucosal as
well as long-term immune stimulations and responses are
required.
Adjuvant selection and formulation can be based on several
parameters including the type of disease, route of vaccination,
vaccine platform, physical and chemical natures of antigen, type
of required immune response and age of the target population.
Moreover, the selection of the wrong adjuvant could reduce
vaccine efficiency. Thus, the selection of vaccine antigens must
take into account the selection of adjuvant to enhance the
potential effectiveness of vaccine candidates (Reed et al., 2013).
Many different types of compounds have been evaluated as
adjuvants for human and animal applications and these include;
mineral salts, microbial products, emulsions, saponins, cytokines,
polymers, NPs, MPs and liposomes. To date, only a few adjuvants
have been used in licensed human vaccines: including Alum (Lee
and Nguyen, 2015), MF59 (composed of squalene droplets
stabilized with surfactants Tween 80 and Span 85) (Ko and
Kang, 2018), squalene-based adjuvant AS03 (Wilkins et al.,
2017), AS04 (monophosphoryl lipid A (MPL) + alum) (Wang
and Xu, 2020), AF03 (squalene-based emulsion adjuvant) (Wang
and Xu, 2020), virosomes and heat-labile enterotoxin (LT)
(Tregoning et al., 2018). Figure 2 shows the timeline of the
development of licensed vaccine adjuvants for humans. Another
application of adjuvants comprises delivery and stabilizing
antigens, which could promote more effective delivery of
immunogens and at the same time enhance antigen-specific
immune responses.
Nanoparticle-Based Delivery System for
Mucosal Vaccine
Even though adjuvants derived from bacteria or plant
components and synthetic materials are immunostimulatory,
many of them exhibited toxicity, leading to undesirable
adverse reactions (Sander et al., 2019). These adjuvants also
lacked the ability to overcome mucosal barriers and deliver the
antigens to mucosal APCs or M cells for processing. NPs are good
delivery systems as they are capable of traversing mucosal barriers
to efficiently target the immune cells, control the duration release
and presentation of antigens. Antigens can either be encapsulated
or surface absorbed or chemically conjugated to the NPs. NPs
represent a promising platform that combines both delivery and
immunostimulatory functions. They have also demonstrated
safety, efficacy and ability to stimulate mucosal and systemic
immune responses (Jazayeri and Poh, 2019).
Nanoparticles and Microparticles
NPs technically range in size from 1 to 1,000 nm (1 μm)
(Jeevanandam et al., 2018) while MPs are particles with sizes
ranging from 1 to 1,000 μm (Lengyel et al., 2019). The size of the
particulate immunogens has different effects on oral distribution,
targeting ability and types of induced immune responses. Small
particles are more efficient in permeating biological barriers,
moving through capillaries and distribute in blood circulation.
NPs with a diameter of 100 nm or less are preferred over larger
particles for targeting drug delivery purposes. Moreover, the size
of particles could affect cellular specificity and migration.
Additionally, small NPs ranging from 20 to 200 nm could
rapidly drain to the lymph nodes (LN), where they could be
taken up by resident DCs. Large NPs from 500 to 1,000 nm are
dependent on cellular transport by DCs, migrating from the
injection site (skin) to LN in vivo. These data suggested that
larger NPs prefer interacting with tissue-resident APCs, while
smaller NPs (<200 nm) could circulate through the vein and
lymphatic drainage, thus providing better antigen presentation
(Liu et al., 2017). Moreover, MPs promote humoral immune
responses whereas NPs tend to favor the induction of cellular
immune responses (Silva et al., 2016). The NPs taken up into M
cells in Peyer’s patches are efficiently transferred to dendritic cells
which can initiate an immune response (Cao et al., 2019).
LIPID-BASED VEHICLES
Liposomes
Liposome technology was established by Bangham and Horne in
the 1960s as a system for the diffusion of ions across biological
membranes and later in the 1970s, there was an interest in drug
delivery applications (Bernasconi et al., 2016). Liposomes could
mimic the natural structure of cell membranes and have long
been investigated as drug carriers due to excellent entrapment
capacity, safety and biocompatibility (He et al., 2019). Liposomes
are spherical vesicles characterized by a bilayer of phospholipids
with an internal aqueous cavity. The injectable formulations of
liposomes have been used as delivery vehicles and licensed for
clinical use (Bulbake et al., 2017).
The cationic liposomes have been extensively considered as an
effective oral vaccine carrier for diverse antigens and
adjuvanticity applications due to their unique properties such
as biodegradability, biocompatibility, surface charge variability,
and membrane fluidity (Table 1). Encapsulation of water-soluble
molecules such as proteins, peptides, nucleic acids, haptens, or
carbohydrates are in the aqueous inner layer while lipophilic
compounds such as lipopeptides, antigens, adjuvants or linker
molecules can be included in the external section of liposomes
(Schwendener, 2014). Liposomes could protect the payload from
Frontiers in Pharmacology | www.frontiersin.org June 2021 | Volume 12 | Article 6822865
Jazayeri et al. Nano and microparticles as Oral Vaccine Carriers
the harsh GI environment, control the release of active drugs and
induced both humoral and cell-mediated immune responses
(Vela Ramirez et al., 2017).
Liposomes significantly protect the delivery of DNA vaccines
in the GI against DNases and promote absorption at the cellular
level. The fusion of liposomes to host cells could facilitate the
internalization of encapsulated DNA vaccine into the cytoplasm
and adjuvanticity of liposomes could enhance the expression of
the recombinant plasmid (Schwendener, 2014).
Wang et al. (2010) constructed a DNA vaccine encoding
Mycobacterium antigen 85A (Ag85A) encapsulated in
liposomes. After three oral vaccinations in mice, the Ag85A
protein antigen was detected in the epithelium, M cells,
dendritic cells (DCs) and Peyer’s patches of the small intestine
and antigen-specific mucosal, systemic humoral and cellular
immunity against tuberculosiswere generated (Wang et al., 2010).
Biopolymer-coated liposomes as a potential carrier was able to
successfully deliver DNA/GFP through the Peyer’s patches of
mice, which are mostly located in the ileum, and extended the
stability of surface charge of the particles which were crucially
important for oral DNA vaccine delivery. The biopolymer such as
chitosan as a biodegradable coating material with liposomes was
found to improve DNA internalization efficiency, reduced DNA
deterioration, increased positive surface charges and facilitated
DNA encapsulation (Channarong et al., 2011). Biopolymers
bonded on the surface of liposomes could change their surface
charge, for example, their surface charge would be positive in the
presence of chitosan. The cationic liposomes were used for oral
delivery of a DNA vaccine encoding the M1 gene of influenza A
virus. Oral immunizations of mice three times at weekly intervals
showed there was expression of the M1 gene in the intestine,
elicited both humoral and cellular immune responses as well as
protection against respiratory challenge. These findings suggested
cationic liposomes in the GI could be considered as a potential
carrier and route for DNA vaccine delivery against viral infections
(Liu et al., 2014).
A variety of liposome-based vaccines as oral carriers were
administered to target a wide range of viral and bacterial diseases
in veterinary medicine. Oral vaccination of chickens with a
liposome-associated carrier with the recombinant SefA (rSefA)
protein from Salmonella enteritidis generated both systemic and
mucosal antibody responses. A significant reduction of intestinal




Liposomes - Biodegradable, biocompatible, non-toxic and non-immunogenic - The formulation is highly dependent on charge and size of the antigen
- Safety due to the resemblance to biomembranes - Instability and poor permeability
- Protect encapsulated hydrophilic, hydrophobic and amphipathic
antigens
- Require special storage
- Can be formulated to NPs or MPs and administered through
various routes
- Encapsulated antigens fail to reach M cells and release/degradation in GI





Bilosomes - Self-adjuvant properties - Unstable in the GI environment
- Do not require special storage
- High antigen encapsulation
- Protect antigens in GI tract, rapid and efficient uptake by M cells
- Induce mucosal immunity at the site and other distant mucosal
sites
PLGA - Biodegradable, biocompatible, and non-toxic - Instability of antigens during encapsulation, drying and storage
- Can be formulated to NPs or MPs
- Various antigens with full antigenicity can be loaded within PLGA-
or PLGA-based conveyor
- Can be recognized by professional APCs
- Approved by the US food and drug administration
ISCOM - Small amounts of encapsulated antigens are immunogenic - Incorporation of many antigens into the structure is difficult
- Induce humoral and cellular immune responses - Not very stable in the gut
Highly stable - Difficult to manufacture
- Strong pain at the injection site
- Strong toxic reactions
Gold NPs - Readily internalized by macrophages and dendritic cells - Accumulate in organs such as liver and spleen for long periods which could
ultimately be associated with toxicity- A wide range of molecules, (adjuvants and antigens) can be
conjugated
- Large scale production is possible
Chitosan - Non-toxic, biodegradable, biocompatible, and has bio-adhesion
ability
- Insoluble at physiological pH in water
- Easy degradation in acidic media such as the GI tract
- Irregular distributions
Alginate - Low toxicity, biocompatibility, biodegradability - Incompatible with heavy metals
- Approved by the U.S. Food and drug administration - Cannot be fully eliminated from our body
- Stable in gastric fluid - Non-degradable in mammals
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bacterial colonization in the Gl tract was observed after an oral
challenge with live Salmonella enteriditis (Pang et al., 2013). Oral
immunization of chickens with commercial Newcastle disease
(ND) vaccine (LaSota strain) and combination of gypenosides
(GPS)/liposome as adjuvant significantly enhanced lymphocyte
proliferations, increased specific antibody titer against ND and
promoted cytokine secretion. Therefore, the results indicated
formulations of GPS and liposome could further enhance the
immune response against ND vaccine compared with GPS or
liposomes alone (Yu et al., 2013). In another study, live ND
vaccine (LaSota strain) encapsulated in 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP)-based liposomes was
used. Chickens orally vaccinated with the liposomal ND
vaccine showed higher antibody titer and indicated
encapsulation of ND vaccine in DOTAP-based liposome
induced significantly higher immunity than the live ND
vaccine (Onuigbo et al., 2012).
H. pylori urease B subunit and cholera toxin B were expressed
and purified in E.coli as a recombinant fusion peptide. The
recombinant fusion peptide was encapsulated in the
phospholipid bilayer vesicle liposome with encapsulation
efficiency of 71.4%. Liposome as the oral carrier could
protect fusion peptide in the GI tract from protease, acids
and other harmful components. Oral vaccinations of mice
with liposome-encapsulated recombinant fusion peptide
administered at four weekly intervals were able to increase
the specific IgG and IgA antibodies as well as providing
prophylactic and therapeutic effects against H. pylori
infection (Zhao et al., 2007). In another study, Dhakal et al.
(2018) used liposome NPs as a carrier to incorporate ten highly
conserved T and B cell epitope peptides. Intranasal mist
immunization of pigs with liposomal conserved peptide
vaccines was found to enhance the frequency of peptide
specific cellular (virus-specific T-helper/memory cells) and
mucosal humoral immune responses (Dhakal et al., 2018).
Released fractions of labile biomacromolecules are degraded
quickly and will not be absorbed through GI and only liposomes
that could survive in the GI environment and manage to
penetrate the mucus layers could reach the intestinal epithelia
and be absorbed together with the payloads. The initial challenge
to enhance the oral absorption of liposomes as well as the
payloads was to maintain the integrity of liposomes and
prolong gastrointestinal residence, thus enhancing penetration
of the mucus layers. Recent advances are focused on modulating
the compositions of the lipid bilayers or modifying the liposomal
surfaces with polymers or ligands to modulate the in vivo fate of
liposomes after oral administration (He et al., 2019).
NANOSTRUCTURED LIPID CARRIER
Nanostructured Lipid Carrier (NLC) is a type of lipid NPs
containing a hydrophobic solid and liquid lipid core covered
by the surfactant monolayer (Gómez-Aguado et al., 2020).
Compare to other lipid systems, NLC possessed the
advantages of low toxicity, simple production, can be
subjected to sterilization and is more affordable (Beloqui
et al., 2017). NLCs were primarily considered for the
delivery of lipophilic drugs but their suitability for
hydrophilic drugs is now well established (Salvi and Pawar,
2019).
NLC has been recognized as a nano-delivery solution to
increase the oral bioavailability of poorly soluble drugs
(Beloqui et al., 2014). Interestingly, recent studies have
reported the potential of using NLC to deliver replicating viral
RNA (rvRNA) (Erasmus et al., 2018) and HIV p24 peptide
vaccines (Bayon et al., 2018) to achieve protection in the in
vivo studies. However, both studies delivered the NLC-rvRNA
and HIV p24 peptide vaccines through intramuscular (IM) and
intraperitoneal injections (IP), respectively. Thus, further studies
to evaluate the potential or even to improve the formulation of the
NLC-mRNA or NLC-peptide vaccines as oral vaccines can be
considered.
Bilosomes
In addition to traditional liposomes, bilosomes are non-ionic
lipid-based vesicles (niosomes) containing biodegradable and
biocompatible bile salts (sodium deoxycholate). They have
been extensively used for oral vaccine delivery due to their
adjuvanting properties, encapsulation of antigens, flexible size
formation, and rapid uptake by M cells (Table 1). Recently,
several studies have been performed using the bilosomes as a
carrier for oral vaccine delivery and was reported to efficiently
induce mucosal sIgA immunity at local and other distant
mucosal sites.
As most of the hepatitis B vaccines were administered via
the parenteral route and they failed to provide mucosal
immune responses, oral vaccination could be considered as
an alternative to overcome this failure. Oral immunization of
mice with bilosomes containing the recombinant hepatitis B
surface antigen was found to increase uptake of bilosomes
entrapped in gut-associated lymphoid tissues and produced
both systemic as well as mucosal antibody responses (Shukla
et al., 2008).
Jain et al. (2005) showed mannosylated bilosomes
encapsulating DNA vaccine encoding the hepatitis B antigen
could be used as an oral carrier-adjuvant. The mannan coating
stabilized the bilosomes throughout the GI tract and also targeted
the mannose receptors present on dendritic and macrophage
cells. Oral vaccinations of mice with the modified bilosomes
induced measurable cellular and humoral immune responses,
as well as neutralizing sIgA which was considered as a key
antibody produced during mucosal immune responses (Jain
et al., 2005).
Glucomannosylated bilosomes containing BSA were found to
induce mucosal, systemic as well as cell mediated immune
responses (Jain et al., 2014). Oral vaccinations of mice with
recombinant baculovirus displaying VP1 from human
enterovirus 71 associated with bilosomes elicited significant
VP1-specific humoral IgG and IgA immune responses
(Premanand et al., 2013). In another study, diphtheria toxoid
(DTx) loaded with nano-bilosomes was significantly
immunogenic when administered orally in mice. Significant
anti-DTx IgG and anti-DTx sIgA antibodies were detected in
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serum and mucosa of vaccinated mice, respectively (Shukla et al.,
2011).
The optimized bilosome formulation was assessed as an oral
vaccine delivery system with respect to its biodistribution and
vaccine efficacy. The larger bilosome vesicles (∼6 vs. 2 µm in
diameter) were demonstrated to have increased uptake within the
Peyer’s patches. Oral immunization of ferrets with recombinant
hemagglutinin (HA) incorporated into bilosome was able to
reduce fever, suppressed lung inflammation and reduced viral
load in the influenza challenge model. Thus, the bilosome has
shown promising results as an oral vaccine carrier and could
induce higher immune responses (Wilkhu et al., 2013).
Oral immunizations of mice using HA entrapped in bilosomes
with particle sizes between 400–2000 nm elicited an immune
response that was significantly biased towards Th1 as measured
by serum antigen-specific IgG2a and splenocyte IFN-γ
production rather than vaccination using bilosomes with size
10–100 nm (Mann et al., 2009). These results showed oral vaccine
formulations could be physically modified to improve the
effectiveness of vaccines to manipulate the required immune
responses.
Oral immunization of bilosomes was able to induce both
mucosal and systemic immune responses. Surface modification
of bilosomes with anchoring ligands demonstrated their potential
to target specific immune cells. Availability and low cost of bile
salts and acids could thus transform such chiral carriers into
attractive building blocks for targeting novel drug carrier systems.
Moreover, bilosomes could enhance the bioavailability of drugs,
increase the efficacy of drugs and the ability to entrap proteins,
peptides and antigens (Palekar-Shanbhag et al., 2020).
IMMUNE-STIMULATING COMPLEXES
ISCOMs were first described by Morein et al. (1984) as a vaccine
delivery vehicle (Bigaeva et al., 2016). ISCOMs are cage-like
structures of 30–40 nm in diameter composed of glycosides
that are present in cholesterol, Quil A, antigens and
phospholipids (Fleck et al., 2019).
Oral vaccination with ISCOMs incorporating Herpes simplex
virus type 2 (HSV-2) antigens (HSV-specific glycoproteins, gB2,
gD1, gE1, and gG2) were able to induce high levels of IgA and IgG
(systemic and local) as well as conferring sufficient protection
against heterologous lethal dose of HSV-2 in mice (Mohamedi
et al., 2001). In another study, ISCOMS containing a fusion
protein comprising the OVA323–339 peptide epitope linked to
CTA1-DD (a mucosal adjuvant) were highly immunogenic when
administered by the subcutaneous (s.c.), oral, or nasal routes and
induced a wide range of T cell-dependent immune responses as
well as systemic immune responses (IgG2a and IgG1 isotypes).
Their results demonstrated that ISCOMs could induce a broad
range of cellular and humoral immunity (Mowat et al., 2001).
Oral immunization of mice with two doses of influenza
A/Sichuan/87 ISCOM vaccine were able to elicit robust
humoral IgG2a subclass antibody and conferred protection
against homologous virus challenge. The results demonstrated
that ISCOM could be considered as a potential oral delivery
system and provided adjuvanticity for viral antigens (Ghazi et al.,
1995). Most of the available adjuvants in the market mainly
activate the humoral immune response and there is a clear need
for vaccines to induce a cellular immune response as well. ISCOM
as an adjuvant could induce strong activation of both humoral
and cellular immune responses and enhance the generation of
most classes and sub-classes of antibodies.
METAL-BASED NANOPARTICLES
Gold Nanoparticles
Gold (Au) has been used extensively in nano-medicine (in the
form of NPs) due to its therapeutic effects on several diseases.
Gold could also play an important role in the vaccine
development field as a carrier and an adjuvant, enhancing the
immunogenicity of antigens, reducing toxicity, and providing
stability (Table 1) (Carabineiro, 2017).
The combination of delivery systems and adjuvants have been
used to maximize the efficacy of mucosal vaccines. Chitosan
functionalized gold NPs (CsAuNPs) were used as a carrier for
tetanus toxoid (TT) as an antigen model along with the
immunostimulant of Quillaja Saponaria extract (QS) as an
adjuvant. Oral immunization of mice with CsAuNPs-TT-QS
induced up to 28-fold immune responses (TT-specific IgG and
IgA) compared to TT and TT-QS controls. Thus, combination of
adjuvants with NPs can play an important role in the efficacy and
stability of mucosal vaccines (Barhate et al., 2013).
The mucosal adjuvanticity of Asparagus racemosus extract
(ARE) in oral delivery of TT using CsAuNPs as a carrier was
evaluated in the murine model. A significant local and systemic
increase in TT-specific IgG and IgA were observed when TT-
CsAuNPs were formulated and delivered with ARE. As an
immunomodulatory adjuvant for mucosal delivery of vaccines,
ARE showed no effect on charge, size and loading properties of
CsAuNPs. Additionally, ARE and CsAuNPs were observed to
have no effects on antigenicity and the secondary structure of TT
(Barhate et al., 2014).
Silver Nanoparticles
Metallic NPs are relatively non-biodegradable, have rigid
structures and are simple to synthesize. Currently, for green
synthesis processing of metallic NPs, biological materials such
as bacteria, plants and algae are usually used as capping groups
and reducing agents. AgNP is one of the most vital and
fascinating nanomaterials among several metallic NPs which
have been exponentially used as antimicrobial and larvicidal
agents because of the lower cost of production as well as the
simplicity of synthesis. Recently, several studies have been
conducted to use green synthesis NPs as adjuvants to increase
the immunogenicity of antigens (Marslin et al., 2018).
AgNPs produced by the reduction of aqueous silver nitrate
using leaf extract of Eucalyptus procera were evaluated to see if
the immune response against inactivated rabies virus in the
murine model was enhanced. The results were compared with
commercially available alum adjuvant. The adjuvanting effects of
green synthesized AgNPs on the potency of veterinary rabies
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vaccine were demonstrated with no in vivo toxicity (Asgary et al.,
2016).
Jazayeri et al. (2012) synthesized green AgNPs by using PEG
and β-D-glucose as stabilizer and reducing agents, respectively.
Single oral immunization of one-day-old chicks with
encapsulated H5 DNA vaccine with AgNPs rapidly increased
production of antibodies against H5, cellular immune responses
as well as enhanced cytokine productions. Moreover, PCR
successfully detected the encapsulated H5 plasmid from the
duodenum of the vaccinated chickens as early as 1 h post-
immunization. Although there are some concerns about the
toxicity of silver-based NPs, no toxicity induced by AgNPs as
a carrier for oral DNA vaccine was observed in chickens (Jazayeri
et al., 2012).
POLYMERIC NPS
In recent years, synthetic polymer-based NPs/MPs have received
more attention for their roles in vaccine delivery and
adjuvanticity due to their ease in preparation, biocompatibility,
biodegradability, stability in the biological environment, low
cytotoxicity, protective, controlled and sustained-release of
encapsulated substances (Calzoni et al., 2019).
Poly(Lactic-co-Glycolic Acid)
The most commonly used synthetic biodegradable polymer-
based NPs for vaccine delivery and adjuvanticity is PLGA.
PLGA is a highly compatible copolymer of poly-lactic acid
(PLA) and polyglycolic acid (Letchford and Burt, 2007). PLGA
NPs can be easily loaded with a wide variety of molecules and
have been approved for human and veterinary drug delivery by
the American Food and Drug Administration (FDA) (Table 1)
(Cappellano et al., 2019). PLGA based NPs could protect antigens
in the harsh GI environment by surface attachment or
encapsulation mechanisms using ionic or covalent bonding
(Moon et al., 2012).
PLGA vaccine/adjuvant encapsulation could provide slow
release of antigens and adjuvants which could stimulate innate
immune responses and potentially induced both mucosal and
systemic immune responses as well as improving humoral and
long-term memory CD8 T cell (Kasturi et al., 2011; Demento
et al., 2012). Besides encapsulation, the antigens could be
adsorbed on the surface of PLGA by electrostatic or
hydrophobic interactions (Pakulska et al., 2016).
Ashhurst et al. (2018) developed biodegradable PLGA as a
carrier for the M. tuberculosis lipoprotein MPT83 together with
the adjuvant trehalose-dibehenate (TDB) or Monophosphoryl
lipid A (MPL). Mucosal immunization of mice with PLGA-
encapsulated protein-based subunit vaccine was found to
stimulate strong anti-MPT83 antibody or Th17 responses and
PLGA could be considered as a potential carrier for vaccines
against extracellular pathogens (Ashhurst et al., 2018).
PLGA-lipid NP hybrids were shown to be able to transfect
plasmid DNA encoding a luciferase reporter gene into cells. The
method of DNA loading to NPs, either absorbed on the outer
surface or encapsulated within the NPs could affect the uptake of
the NPs by the adherent and non-adherent cells, as well as the
release of DNA (Zhong et al., 2010). Golan-Paz et al. (2018)
developed a novel core-shell NP-based PLGA (core) and a
multilamellar lipid shell when lipid bilayers are cross-linked
between the two adjacent bilayers (PLGA-ICMVs). The
PLGA-ICMV platform demonstrated great potential for
encapsulating water-soluble biological agents such as protein
and DNA plasmids and therefore could be considered as a
promising candidate for therapeutic vaccine delivery (Golan-
Paz et al., 2019).
The outer membrane protein W (OmpW) of Aeromonas
hydrophila was cloned, purified, and encapsulated in PLGA
NPs for oral vaccination of rohu (Labeo rohita Hamilton). The
results showed oral administration of encapsulated OmpW using
PLGA could provide dose-dependent protection against A.
hydrophila infection in fish (Dubey et al., 2016).
To improve the efficacy of oral vaccine delivery, Taha-
Abdelaziz et al. (2018) exploited PLGA for encapsulation
and delivery of CpG to effector sites in the GI tract. Oral
administration of PLGA-encapsulated oligodeoxynucleotides
(ODN) containing unmethylated CpG and C. jejuni lysate
enhanced the ability of CpG to reduce Campylobacter load
in both layer and broiler chickens (Taha-Abdelaziz et al.,
2018). In another trial by Alkie et al. (2017), encapsulated
CpG with PLGA as a carrier showed higher and sustained
innate immune responses in chicken macrophages and
splenocytes compared to the naked soluble form of CpG
(Alkie et al., 2017). The hydrophobic polymeric PLGA
stabilized by one layer of phospholipids embedded in the
surface area was used as oral vaccine delivery for
Ovalbumin (OVA). Compared with the pure PLGA NPs,
the lipid NPs achieved higher loading capacity and
entrapment efficiency for the encapsulated OVA. Although
the phospholipids were in a narrow size around PLGA, they
showed all the applicable characteristics of both polymeric and
liposome NPs, like preventing vaccine degradation, enhancing
cellular absorption and low toxicity (Ma et al., 2014a).
Injured brain microvascular endothelial cells (BMECs)
overexpressed tissue factor (TF) which was targeted by the
fusion protein EGFP-EGF1 nanoparticles loaded with TF
siRNA as a potential treatment. EGFP-EGF1 conjugated PLGA
NPs (ENP) were used as a new targeted carrier for TF-specific
siRNA which could be effectively delivered to atherosclerotic
plaques in vivo and taken up by mouse vascular smooth muscle
cells with high TF expressions in vitro. The data showed that the
ENP-based transfections resulted in efficient downregulation of
TF (Chen et al., 2013).
Ma et al. (2014) developed ulex europaeus agglutinin-1 (UEA-
1) conjugated PLGA-lipid NPs containing a Toll-like receptor
(TLR)-agonist monophosphoryl lipid A (MPL) as an oral vaccine
delivery system. Oral immunization of mice with UEA-MPL/
PLGA lipid NPs could protect and released the entrapped OVA
through the GI tract. The entrapped ovalbumin (OVA) was
protected from exposure to the GI tract and the OVA was
released in a controlled manner. These results suggested that
designed OVA-UEA-MPL/lipid NPs could be effectively
transported by M cells, captured by mucosal dendritic cells
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(DCs) and induced mucosal IgA and serum IgG antibodies (Ma
et al., 2014b).
Poly (γ-glutamic Acid)
γ-PGA is a natural and promising biopolymer produced by
several gram-positive bacteria such as Bacillus subtilis. Due to
the unique characteristics of γ-PGA like low toxicity,
biodegradability and biocompatibility with tissues and cells as
well as non-immunogenic properties, it has been used extensively
for vaccine development and pharmaceutical applications.
γ-PGA NPs could induce cellular and humoral immune
responses as well as having great potential as an antigen-
delivery system and vaccine adjuvant (Uto et al., 2013).
Upon oral administration of γ-PGA in mice, the presence of
γ-PGA was found in sub-epithelial dome region of Peyer’s patch
(PP). Orally administered γ-PGA enhanced levels of various
chemokines in intestines, accumulation of CD8 DC subsets in
mesenteric lymph nodes and activation of DCs in Peyer’s patch.
Oral inoculation of mixed γ-PGA with OVA was shown induce
activation of OVA-specific T cells as well as levels of both IgA
(intestinal) and IgG (sera). In the study, OVA was used as the
model protein to develop a protein-based vaccine (Kim et al.,
2019).
Chitosan
Chitosan is a linear polysaccharide predominantly composed of
β-(1–4)-linked D-glucosamine and N-acetyl-D-glucosamine. The
N-acetyl-D-glucosamine moiety of chitosan is recognized by the
mannose receptors on the DCs (Park and Babensee, 2012). The
chitosan with amino and carboxyl groups interact with the
glycoprotein in mucus to form a hydrogen bond which could
produce an adhesive effect and absorption-enhancing properties
for M cells of the follicle-associated epithelium (FAE) (Wang
et al., 2011a). Due to chitosan mucoadhesion and transient
opening of the tight junctions of the mucosal cell membrane,
chitosan showed promising mucosal absorption effects.
Interaction between the positive charge of chitosan and the
negative charge of mucin could increase the contact time
between the drug and the absorptive surface. Moreover, the
mucoadhesion effect of chitosan was shown to increase the
half-life of drug clearance (Ways et al., 2018).
Chitosan has attracted considerable attention as a
biodegradable, non-toxic and biocompatible polymer to
encapsulate a range of vaccines such as DNA, RNA, proteins,
peptides as well as drugs as a novel delivery vehicle for both oral
and intranasal administration. Various studies have shown
chitosan as an oral vaccine delivery system by activation of
macrophages, dendritic cells (DC) and lymphocytes which
induce higher immune responses. Moreover, an ionic
crosslinking method was used to encapsulate Newcastle disease
virus (NDV) with chitosan NPs to enhance the efficacy of a
lentogenic live-virus vaccine against ND. Single oral
immunization of chickens with chitosan-live NDV provided
full protection after challenge with a highly virulent NDV
strain F48E9 (Zhao et al., 2012).
Recently, Renu et al. (2020) developed subunit chitosan NP
based vaccine by using immunogenic outer membrane proteins
(OMPs) and flagellin (F) protein (OMPs-F-CS NPs) of
Salmonella. Oral immunization of layer chickens with OMP-F-
CS NPs led to localization of the nanovaccine in ileal Peyer’s
patches and induced significantly higher OMP-specific mucosal
IgA production as well as lymphocyte proliferation response and
reduced salmonellosis in poultry (Renu et al., 2020).
Chitosan NPs loaded with TOPO TA plasmid encoding
Rho1-GTPase of Schistosoma mansoni were able to complex
electrostatically with the plasmid and condensed it into
positively charged nanostructures. The primary oral
vaccination of mice with chitosan/Rho1-GTPase
nanostructures followed by two boosters at two weekly
intervals were demonstrated to induce high levels of IL-10.
Furthermore, immunization of mice with only chitosan NPs
conferred 47% of protection against parasite infection,
suggesting an important role of chitosan in inducing a
protective immune response against schistosomiasis
(Oliveira et al., 2012). The protonated form of chitosan is
normally water-soluble in acidic pH due to its pKa value of
about 6. In order to improve the solubility and vaccine
delivery, several studies have reported various chemical
modifications of chitosan which improved stability,
membrane permeability, mucoadhesivity and controlled
release behaviour (Xing et al., 2018).
Alginate-coated chitosan microparticles could protect acid-
labile drugs effectively from degradation in acidic pH than
chitosan microparticles alone (Li et al., 2017) and enhanced
antigen uptake by mucosal lymphoid tissues, especially at the
Peyer`s patches (Zhang et al., 2016). Liu et al. (2013) showed
alginate-coated chitosan NPs could be efficient and was observed
to be safe carriers for the oral delivery of legumain DNA vaccines
(Liu et al., 2013). In another study, Onuigbo et al. (2018)
demonstrated oral administration of fowl typhoid vaccine
encapsulated in alginate-coated chitosan microparticles could
induce comparable innate and adaptive immune responses
with the subcutaneous route of administration as well as
protection from S. gallinarum virulent strain (Onuigbo et al.,
2018).
The chitosan-alginate coated calcium phosphate NPs could
protect the antigens in the GI environment against acidic
degradation and enhance the immune response in the small
intestine. The results demonstrated coating with chitosan
enhanced antigen uptake by macrophages and Caco-2
(intestine epithelial cells) as well as improved surface
expression of costimulatory molecules on macrophages. In
vivo oral administration of alginate-chitosan-coated calcium
phosphate-OVA NPs significantly enhanced the mucosal IgA
and serum IgG antibody responses as compared to naked OVA,
indicating that the chitosan- and alginate-coated calcium
phosphate NPs could potentially be used as a promising oral
vaccine delivery system (Cao et al., 2020).
In another study, bovine serum albumin (BSA) was used as a
protein-based vaccine model and was loaded into the
mannosylated chitosan NPs (MCS) by ionic gelation method
with tripolyphosphate (TPP), followed by coating with Eudragit
L100 (Eud) and electrostatic interaction. MCS NPs were
accumulated more specifically into PPs after Eudragit L100
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was dissolved in intestinal juices. Oral immunization of rats by
using BSA-loaded Eudragit L100-coated MCS NPs elicited strong
mucosal IgA and systemic IgG antibody responses. These results
suggested that enteric-coated MCS NPs could serve as a
promising carrier for oral protein-based vaccine delivery (Xu
et al., 2018).
The effectiveness of ionotropic gelation method (by
combining alginate and chitosan) as a bivalent streptococcus-
lactococcus vaccine against Streptococcus iniae and Lactococcus
garvieae was examined in rainbow trout. Oral vaccination of fish
with chitosan-alginate coated microparticle vaccine increased
immunity and improved the survival rate by the expressions
of IL-6 and IgM (Halimi et al., 2019).
Oral immunization of turbots with carboxymethyl chitosan/
chitosan NPs (CMCS/CS) loaded with extracellular products
(ECPs) of Vibrio anguillarum showed elevated specific
antibodies and higher concentrations of lysozyme and
complement activities in fish serum than ECPs. CMCS/CS-
NPs loaded with ECPs could improve both innate and
adaptive immune responses and suggested that it could serve
as a potential oral antigen delivery system in fish (Gao et al.,
2016). The application of chitosan as a polycationic gene carrier
for oral vaccine delivery has been ongoing since the 1990s.
Chitosan NPs could protect DNA based vaccines against
nuclease degradation by forming a polyelectrolyte complex
with the negatively charged nucleotides and also improve the
transfection efficiency. Kumar et al. (2008) used the porin gene of
Vibrio anguillarum to construct a DNA vaccine by using pcDNA
3.1 expression vector. Oral vaccination of Lates calcarifer with
chitosan encapsulated/plasmid complex showed antigen
expression and moderate protection (46%) against V.
anguillarum infection (Rajesh Kumar et al., 2008).
Alginate
Alginate is a hydrophilic anionic polysaccharide obtained from
the brown seaweed. Alginate can be orally administered or
injected and has been extensively investigated in drug and
vaccine delivery due to its low toxicity, biocompatibility,
biodegradability (Lee and Mooney, 2012) and was approved
by the U.S. Food and Drug Administration (Sosnik, 2014). As
alginate is stable in simulated gastric fluid (pH 1.2), it was used to
encapsulate an antigen to protect it from enzymatic degradation
and facilitate its release (Borges et al., 2008).
Oral administration of rabbits and cattle with alginate
microspheres containing Pasteurella multocida and OVA
antigens could produce higher serum IgG, IgA, and sIgA
responses than those immunized with unencapsulated antigens
(Bowersock et al., 1999). In another study, oral immunization of
mice with alginate encapsulated polysaccharide antigen of
Streptococcus pneumonia showed effective protection against
intranasal challenge with S. pneumoniae (Seong et al., 1999).
A formalin-killed L. garvieae TW-446.B3 was encapsulated in
alginate microparticles and fish were orally immunized. The
results demonstrated relative percent survival (RPS) of around
50% and this failed to warrant the efficacy of the vaccine
formulation as a primary vaccination method. In another
study, the efficacy of alginate-encapsulated killed vaccine as a
booster immunization was evaluated 3 months after primary
intraperitoneal immunization of fish with aqueous-based
bacteria. The relative percent survival could reach up to 87%.
These results highlighted the value of alginate encapsulation
which led to an increase in the duration of protection of the
rainbow trout against lactoccocosis (Romalde et al., 2004).
Moreover, Ballesteros et al. (2015) prepared alginate
microparticles for oral delivery of the glycoprotein (G) gene of
infectious hematopoietic necrosis virus (IHNV) to rainbow trout.
The results demonstrated that the alginate microparticles could
protect the DNA vaccine from degradation in the fish stomach
and ensured early vaccine delivery to the hindgut, vaccine passage
through the intestinal mucosa and its distribution through internal
and external organs of vaccinated fish. Furthermore, single oral
administration of encapsulated DNA vaccine in alginate
microspheres induced dose-dependent adaptive immune responses
and significant protection in rainbow trout (Ballesteros et al., 2015).
Bacille Calmette-Guerin (BCG) is the only approved vaccine
against Tuberculosis. This vaccine is currently administered
intradermally and has shown variable effectiveness of between 0
and 80% in various clinical trials (Colditz et al., 1995). As
mycobacteria are generally transmitted through mucosal surfaces,
the delivery of vaccines by mucosal routes can probably provide
better immunity and protection. Intragastric gavage immunization of
mice with BCG entrapped in alginate microspheres induced effective
Th1 response in the spleen and provided effective protection against
intravenous challenge 8 weeks after vaccination (Ajdary et al., 2007).
Moreover, a single oral immunization of BALB/c mice with BCG
encapsulated in alginate microspheres elicited effective mucosal as
well as systemic immune responses in the lung and spleen (Hosseini
et al., 2015). Alginate microspheres have been successfully used to
encapsulate live porcine rotavirus or its recombinant VP6 protein as
well as plasmidDNA for oral immunization ofmice (Kim et al., 2002;
Nograles et al., 2012). These investigations demonstrated alginate
microspheres could be used as an effective oral carrier and adjuvant to
induce effective mucosal and systemic specific immune responses.
The muco-adhesiveness and muco-penetration of alginate increase
the passage of the encapsulated drug through the epithelium, enhance
the local and systemic drug delivery and increase the bioavailability
and release of antigens.
Oral administration of encapsulated OVA (as a model
antigen) in alginate microparticles to calves demonstrated that
encapsulation of OVA in alginate microparticles could
successfully induce pulmonary immunity and increased
antigen-specific IgAs in bronchoalveolar lavage fluids
(Bowersock et al., 1998). These studies showed that alginate
microparticles were effective for encapsulation and oral
administration of vaccines in small (fish, mouse, and rabbit)
and large animals (cattle). However, it has yet to show potency for
oral immunization in human clinical trials.
CARBON NPS
In order to develop an effective oral vaccine carrier,
immunological adjuvant, antigen protection and M cell
antigen uptake, hydrophobic carbon NPs were synthesized by
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taking silica as a template and sucrose as a carbon source. Carbon
NPs provided large mesopores and macropores which could
encapsulate a large amount of antigens and could be
considered as a potential antigen delivery system. Bovine
serum albumin (BSA) was used as an antigen and loaded into
the pores of carbon NPs. Oral immunization of mice with BSA/
carbon NPs induced IgG in serum and mucosal IgA in salivary,
intestinal and vaginal secretions as well as both T helper 1 and
helper 2 mediated immune responses (Wang et al., 2011b).
CONCLUSION
Oral vaccine development is complex and is considered the most
challenging vaccination method due to the route of
administration. Current licensed oral vaccines target mainly
enteric pathogens and viruses that invade via the intestinal
mucosa. In the last few years, material science applications in
the field of vaccine development are growing rapidly and showed
some promising results. Although the development of human
oral vaccines have not been so successful, biocompatible and
biodegradable NPs/MPs as vaccine carriers in animal models
offer promising and novel vaccination methods that might act
synergistically both as a delivery vehicle and an adjuvant.
Engineered NPs/MPs have demonstrated their potentials to
ensure the induction of both cellular and humoral immune
responses as well as offering much greater advances for the
future development of oral vaccines for humans. The progress
of developing oral vaccines required careful consideration of
multiple physicochemical and biological barriers in the GI
tract as well as delivery systems and adjuvants. However, with
increased understanding of intestinal biology, mucosal immunity
and the next generation of NPs/MPs as vaccine carriers and
adjuvants, there is great hope to address the limitations and
develop more novel oral vaccines.
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